Q2 INTERIM REPORT April-June 2024
Read more
Mentice has received a 2.26 million USD order for simulation solutions from a top 20 global MedTech company
Read more

Extraordinary shareholders’ meeting held on August 28, 2019 elects three new board members in Mentice AB

Wednesday, August 28, 2019

The extraordinary shareholders’ meeting held in Mentice AB on August 28, 2019, elected three additional board members.

The extraordinary shareholders’ meeting held on August 28, 2019 in Mentice AB, elected three additional board members proposed by the nomination committee. The extraordinary shareholders’ meeting thereby extended the number of board members in Mentice AB from four to seven members.

The three new board members of Mentice AB consist of Denis Gestin, Gösta Johannesson and David Ballard.

Denis Gestin, born in 1964, B.Sc in Business Administration and Economics, chairman of the board in Holistick Medical, France and Endo Tools Therapeutics and board member of CathVision. Denis Gestin is independent in relation to the company, its management and major shareholders.

Gösta Johannesson, born in 1959, B.Sc in Business Administration and Economics, senior adviser Bure Equity, chairman of the board XVIVO Perfusion, Idevall & Partners fonder, deputy chairman of Interflora and Axiell Group, board member of Yubico, Scandinova and others. Gösta Johannesson is independent in relation to the company, its management but not in relation to one major shareholder.

David Ballard, born in 1956, B.Sc. in Economics, Medical Doctor degree, M. Sc. In Public Health and PhD in Epidemiology, Executive Vice President and Chief Clinical Officer in Mentice and member of the advisory committee for Mentice Inc and Robbins Institute for Health Policy and Leadership, Baylor University. David Ballard is independent in relation to the major shareholders but not in relation to the company and its management. From being elected as a member of the board, David Ballard will be operating purely as a consultant for Mentice and will consequently immediately leave his line management positions and his seat in the executive management team.

For more information, please contact:

Göran Malmberg, CEO, Mentice

E-post: goran.malmberg@mentice.com

US Mobile: +1 (312) 860 5610

Sweden Mobile: +46 (0) 703 09 22 22

Marketplace| Nasdaq First North Premier, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

Q2 DELÅRSRAPPORT April-Juni 2024
Läs mer
Mentice får en order på simuleringslösningar värd 2,26 miljoner USD från ett topp 20 globalt medtech bolag
Läs mer

Extraordinary shareholders’ meeting held on August 28, 2019 elects three new board members in Mentice AB

Wednesday, August 28, 2019

The extraordinary shareholders’ meeting held in Mentice AB on August 28, 2019, elected three additional board members.

The extraordinary shareholders’ meeting held on August 28, 2019 in Mentice AB, elected three additional board members proposed by the nomination committee. The extraordinary shareholders’ meeting thereby extended the number of board members in Mentice AB from four to seven members.

The three new board members of Mentice AB consist of Denis Gestin, Gösta Johannesson and David Ballard.

Denis Gestin, born in 1964, B.Sc in Business Administration and Economics, chairman of the board in Holistick Medical, France and Endo Tools Therapeutics and board member of CathVision. Denis Gestin is independent in relation to the company, its management and major shareholders.

Gösta Johannesson, born in 1959, B.Sc in Business Administration and Economics, senior adviser Bure Equity, chairman of the board XVIVO Perfusion, Idevall & Partners fonder, deputy chairman of Interflora and Axiell Group, board member of Yubico, Scandinova and others. Gösta Johannesson is independent in relation to the company, its management but not in relation to one major shareholder.

David Ballard, born in 1956, B.Sc. in Economics, Medical Doctor degree, M. Sc. In Public Health and PhD in Epidemiology, Executive Vice President and Chief Clinical Officer in Mentice and member of the advisory committee for Mentice Inc and Robbins Institute for Health Policy and Leadership, Baylor University. David Ballard is independent in relation to the major shareholders but not in relation to the company and its management. From being elected as a member of the board, David Ballard will be operating purely as a consultant for Mentice and will consequently immediately leave his line management positions and his seat in the executive management team.

For more information, please contact:

Göran Malmberg, CEO, Mentice

E-post: goran.malmberg@mentice.com

US Mobile: +1 (312) 860 5610

Sweden Mobile: +46 (0) 703 09 22 22

Marketplace| Nasdaq First North Premier, Stockholm | Ticker symbol MNTC

Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399